Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL). However, the limited ability of JAK inhibition...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Kucine, Nicole, Marubayashi, Sachie, Bhagwat, Neha, Papalexi, Efthymia, Koppikar, Priya, Sanchez Martin, Marta, Dong, Lauren, Tallman, Marty S., Paietta, Elisabeth, Wang, Kai, He, Jie, Lipson, Doron, Stephens, Phil, Miller, Vince, Rowe, Jacob M., Teruya-Feldstein, Julie, Mullighan, Charles G., Ferrando, Adolfo A., Krivtsov, Andrei, Armstrong, Scott, Leung, Laura, Ochiana, Stefan O., Chiosis, Gabriela, Levine, Ross L., Kleppe, Maria
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2015
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661170/
https://ncbi.nlm.nih.gov/pubmed/26443624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-635821
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller